NATIONAL PATIENT GROUP DIRECTION FOR URGENT PROVISION OF MEDICINES, APPLIANCES AND ACBS PRODUCTS.

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS.

IT IS THE RESPONSIBILITY OF THE INDIVIDUAL TO ENSURE THEY ARE USING THE MOST UP TO DATE PGD

1. Authorisation

Developed on behalf of NHS Scotland by NHS 24 by:

Physician	Dr Laura Ryan	Signature	
Pharmacist	Dr John McAnaw	Signature	
NHS Scotland Representative	Mr Jim Miller	Signature	

Authorised for use on behalf of NHS Ayrshire & Arran Health Board by

Medical Director	Crawford McGuffie	Signature	
Senior Pharmacist	Roisin Kavanagh	Signature	
PGD Group Chair	Jen Pennycook	Signature	

Date Approved 22/06/2023

Effective from 22/06/2023 Expires 01/10/2024

2. Management of the Patient Group Direction (PGD)

This PGD must be read, agreed to and signed by all pharmacists involved in its use. The original signed copy should be held by the Health Board.

3. Application

This PGD covers the urgent provision of current NHS prescribed medicines, appliances and ACBS products to NHS patients by pharmacists where there is a clinical need, it is clinically appropriate to make the supply and when the patient's prescriber is unavailable.

4. Clinical Condition

Situation	The provision from a pharmacy with an NHS contract of NHS prescribed medicines, appliances and ACBS products required when the patient is unable to obtain a prescription for supply in the normal way for the clinical conditions described in part A in the schedules of this PGD.
Inclusion Criteria	Medicines and/or appliances and/or ACBS products requested by patient and are currently being prescribed by patient's prescriber (see **Note 1**). Medicines and/or appliances and/or ACBS products are allowed on NHS prescription and are not listed in part B in the schedules of this PGD. The prescriber is unavailable. Patient is registered (or temporarily) with a medical practice in Scotland. Patient agrees to relevant clinical information being provided to the pharmacist. Patient agrees that all relevant clinical information is shared between their prescriber and the pharmacist.
Exclusion Criteria	Provision is not urgent. Medicines and/or appliances and/or ACBS products which are listed in part B in the schedules of this PGD or are not allowed on NHS prescription. No agreement to share relevant clinical information. Patient's clinical condition significantly changed.
Action if Excluded	Provide supply under existing emergency supply regulations. Refer to prescriber or to OOH service using the direct referral process if emergency supply regulations do not apply.

Note 1

The PGD not only covers the urgent supply of a repeat prescription item, but permits the supply of a medicine in a number of other situations thereby bringing it into line with current emergency supply regulations. Below are some scenarios where an urgent supply can be given supporting continuity of patient care (not an exhaustive list):

- Patient recently discharged from hospital with new medication and has not organised a further supply of medication with their own prescriber who is now unavailable
- Acute prescribed medication that has been lost, stored incorrectly, or smashed bottle
- Medication that is prescribed regularly but may not be on a repeat prescription - for example antidepressants
- Patient has been prescribed an acute medication, but prescription has not been forwarded/received in the pharmacy and prescriber unavailable – information held on Emergency Care Summary (ECS) obtained directly by the pharmacy or through NHS 24 would enable supply *
- Patient prescribed medication which they cannot swallow, and they require a liquid preparation
- Alternative flavour of same antibiotic if child unable to tolerate dispensed medication, or indeed capsule or tablet formulation if this resolves the situation
- Supply alternative formulation if dispensed medication is not suitable for other reasons e.g. allergy to excipient, religious reason e.g. beef gelatine
- Acute supplies of rescue antibiotic for COPD patients, many patients keep rescue antibiotic prescription but may have used the last one without renewing it
- Dispense remaining balance of antibiotic when original dispensing pharmacy is closed

* If you are unable to access ECS, then please contact your Health Board to have this rectified. Details of individual Health Boards can be found on the NHS Community Pharmacy website via the following link contact your Health Board. There is also guidance on accessing/troubleshooting ECS on the Community Pharmacy Scotland (cps.scot) website.

5. Description of Treatment

Medicine	All medicines and/or appliances and/or ACBS products required and listed in BNF and BNFC described in part A in the schedules of this PGD.
Legal Status	As described in the BNF or BNFC.
Dosage Form and Strength	As normally prescribed by the patient's prescriber. or Variation of product brand and/or dosage form and/or strength may be substituted when usual product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent.
Dose	As normally prescribed by the patient's prescriber or if not known as recommended by the BNF or BNFC.
Exceptions	All medicines and/or appliances and/or ACBS products listed in part B in the schedules of this PGD.
Duration of Supply	One prescribing cycle i.e. quantity and duration normally prescribed to patient or up to one month's supply if not known.
Patient Information	Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet. Provision of any other relevant information as judged by the pharmacist operating under this PGD.
Documentation	The pharmacist will complete a Universal Claim Framework (UCF) entry within the patient's PMR, producing a completed CP4 form detailing the supply made.
Supply	The supply of medicine and/or appliances and/or ACBS products should comply with the requirement for labelling and be in an appropriate container or packaging.
Follow-up	Ensure that the patient's prescriber is notified and that all records are completed.
Adverse reactions	As described in BNF or BNFC.

Record/Audit Trail	The UCF electronic claim is automatically forwarded to NHS NSS for processing
	A record of the transaction i.e. CP4 form print out, should be forwarded to the patient's prescriber as soon as possible for information.
	A record of the transaction should automatically be entered in the patient's Prescription Medication Record.

6. Characteristic of Staff

Qualifications Required	Pharmacist whose name is currently on the practising section of the pharmaceutical register held by the General Pharmaceutical Council (GPhC).

SCHEDULE 1

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Gastro-intestinal system, chapter 1

Part A: All medicines in Gastro-intestinal system, chapter 1 of the current BNF/BNFC [1], with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Chronic bowel disorders	Food allergy	Rectal and anal disorders
Constipation[2] and bowel cleansing	Gastro-intestinal smooth muscle spasm	Exocrine pancreatic insufficiency
Diarrhoea	Liver disorders and related conditions	Stoma care
Gastric acid disorders and ulceration	Obesity	

Part B: The following medicines listed in Gastro-intestinal system, chapter 1 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 2.1	Acute use only
Chenodeoxycholic Acid	Specialist use only
Cholic Acid	Specialist use only
Obeticholic acid	Specialist use only
Odevixibat	Specialist use only
Opium	Specialist use only/controlled drug

[1] Supply of azathioprine, ciclosporin, mercaptopurine and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page14)

[2] Supply of sodium citrate products for treating constipation is allowed under this section of the PGD

SCHEDULE 2

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Cardiovascular system, chapter 2

Part A: All medicines in Cardiovascular system, chapter 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Arrhythmias	Blood pressure conditions	Myocardial ischaemia
Bleeding disorders	Heart failure	Oedema
Blood clots	Hyperlipidaemia	Vascular disease

Part B: The following medicines listed in Cardiovascular system, chapter 2 of the current BNF/BNFC may NOT be provided under this PGD.

Excluded drug	**Rationale**
All injections, infusions and intravenous flushes **except**: injections for self-administration: Evolocumab Bemiparin sodium Dalteparin sodium Enoxaparin sodium Tinzaparin sodium	Acute/Specialist use only
All section 2.1	Specialist use only
All section 2.2	Acute/Specialist use only
All section 4.1a	Specialist use only
All section 4.1c	Specialist use only
All section 4.2 **except**: Midodrine HCl	Specialist use only
Vericiguat	Hospital use only
Lomitapide	Specialist use only
Mexiletine	Specialist use only

SCHEDULE 3

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Respiratory system, chapter 3

Part A: All medicines in Respiratory system, chapter 3 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Airways disease, obstructive	Conditions affecting sputum viscosity
Allergic Conditions [3]	Cough and congestion

Part B: The following medicines listed in Respiratory system, chapter 3 of the current BNF/BNFC may NOT be provided under this PGD.

Excluded drug	Rationale
All injections [3] and infusions	Acute/Specialist use only
All section 3.1 **except**: Dornase alfa	Specialist/Hospital use only
All section 5	Specialist/Hospital use only
Berotralstat	Hospital use only
Erdosteine	Acute use only
Grass pollen extract	Specialist use only
House dust mite extract	Specialist use only
Peanut protein	Specialist use only
Oxygen [4]	Alternative supply route

[3] Supply of adrenaline (Emerade® EpiPen® Jext®) for self-administration to treat anaphylaxis is allowed under this schedule of the PGD
[4] Oxygen supplies should be obtained via Dolby Vivisol on 0800 833 531

SCHEDULE 4

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Nervous system, chapter 4

Part A: All medicines in Nervous system, chapter 4 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Dementia	Nausea and labyrinth disorders	Sleep disorders
Mental health disorders	Pain	Substance dependence
Movement disorders	Epilepsy and Other Seizure disorders [5]	

Part B: The following medicines listed in Nervous system, chapter 4 of the current BNF/BNFC may NOT be provided under this PGD.

Excluded drug	**Rationale**
All injections and infusions	Acute/Specialist use only
All section 3.2 **except**; Atomoxetine, Guanfacine	Controlled drug
All section 8.3	Controlled drug/Specialist use
Aprepitant	Specialist use only
Buprenorphine	Controlled drug
Cannabidiol	Specialist use only
Capsaicin patches	Specialist use only
Clobazam [6]	Epilepsy only
Clozapine [7]	Registration required
Codeine phosphate oral solution	Potential for abuse
Dipipanone hydrochloride with cyclizine	Controlled drug
Fenfluramine	Specialist use only
Fentanyl	Controlled drug
Gabapentin	Controlled drug
Hydromorphone hydrochloride	Controlled drug
Loxapine	Specialist/Hospital use only
Methoxyflurane	Close medical supervision only
Midazolam [8]	Controlled drug
Morphine [9]	Controlled drug
Morphine with cyclizine	Controlled drug
Nabilone	Controlled drug/Hospital Use
Oxycodone Hydrochloride	Controlled drug
Oxycodone with naloxone	Controlled drug
Palonosetron	Specialist use only
Palonosetron with netupitant	Specialist use only
Paracetamol with tramadol	Controlled drug

Pentazocine	Controlled drug
Pethidine hydrochloride	Controlled drug
Pregabalin	Controlled drug
Sodium Oxybate	Specialist use only
Solriamfetol	Hospital use only
Tapentadol	Controlled drug
Temazepam	Controlled drug
Tramadol	Controlled drug
Tryptophan	Specialist use only

[5] Patients receiving therapy with Category 1 antiepileptics - phenytoin, carbamazepine, phenobarbital or primidone- should be maintained on their usual brand. Patients receiving therapy with Category 2 antiepileptics - the need for continued supply of a particular manufacturer's product should be based on clinical judgement, taking in to account factors such as seizure frequency and treatment history. (MHRA/CHM-Nov 2013)

[6] Clobazam **can** be supplied under the PGD for **epilepsy only and must be endorsed SLS.**

[7] Clozapine **can** be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that

[8] Midazolam oromucosal solution can only be supplied under this PGD for the emergency treatment of **status epilepticus**

[9] All strengths **are not** allowed on the PGD including oramorph 10mg/5ml

SCHEDULE 5

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Infections, chapter 5

Part A: All medicines in Infections, chapter 5 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Amoebic infection	Fungal infection	Nocturnal Leg Cramps
Bacterial infection	Viral infection	

Part B: The following medicines listed in Infections, chapter 5 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 1	Acute use only
All section 4	Acute use only
All section 5 **except** Quinine for nocturnal leg cramps	Acute use only
All section 6.1 **except** Molnupiravir for mild to moderate COVID-19	Specialist use only
All section 6.3a and 6.3b	Specialist use only
All section 6.6	Acute use only
Amikacin	Hospital use only
Fidaxomicin	Acute use only
Delafloxacin	Hospital use only
Isavuconazole	Hospital use only
Letermovir	Hospital use only
Linezolid	Specialist use only
Tedizolid	Acute use only
Neomycin	Acute use only
Posaconazole	Hospital use only
Rifaximin	Acute use only
Tobramycin	Acute use only
Vancomycin	Acute use only

SCHEDULE 6

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Endocrine system, chapter 6

Part A: All medicines in Endocrine, chapter 6 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Antidiuretic hormone disorders	Bone metabolism disorders	Sex hormone responsive conditions
Corticosteroid responsive conditions	Dopamine responsive conditions	Thyroid disorders
Diabetes mellitus and hypoglycaemia	Gonadotrophin responsive conditions	

Part B: The following medicines listed in Endocrine system, chapter 6 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions **except** in section 4	Acute/Specialist use only/Controlled drug
Section 3.1	Specialist use only
All section 7	Specialist use only
All section 8.2 **except** section 8.2a	Controlled drug
Iodide with iodine	Acute use only
Tolvaptan	Hospital use only

SCHEDULE 7

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Genito-urinary system, chapter 7

Part A: All medicines in Genito-urinary system, chapter 7 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Bladder and urinary disorders	Erectile and ejaculatory conditions
Contraception	Vaginal and vulval conditions

Part B: The following medicines listed in Genito-urinary system, chapter 7 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions **except** Section 3.5	Acute/Specialist use only
All intra-uterine devices	Time period between repeats
All section 2	Specialist use only
All section 3.2	Time period between repeats
All section 3.3	Acute use only
All section 6	Specialist use only

SCHEDULE 8

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Malignant disease, chapter 8

Part A: All medicines in Malignant disease, chapter 8 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Immune system [10]	Malignant disease

Part B: The following medicines listed in Malignant disease, chapter 8 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All Immune System drugs excluded **EXCEPT**: **Azathioprine** (oral) for immunosuppression and the treatment of Crohn's disease, rheumatoid arthritis, Systemic Lupus Erythematosus, refractory eczema, myasthenia gravis **Ciclosporin** (oral) [10] for immunosuppression and the treatment of severe ulcerative colitis, severe RA, severe atopic dermatitis, severe psoriasis, nephrotic syndrome **Sirolimus** **Tacrolimus** (oral) [10] **Mycophenolate mofetil** (oral)	Acute/Specialist use only
All Malignant Disease drugs excluded **EXCEPT**: **Mercaptopurine** (oral) for the treatment of Crohn's, ulcerative colitis **Methotrexate** (oral and subcutaneous injections for self-administration) for the treatment of severe Crohn's, severe rheumatoid arthritis, severe psoriasis **Anastrazole** **Bicalutamide** **Diethylstibestrol** **Enzalutamide** [11] **Exemestane** **Flutamide** **Lanreotide** **Letrozole** **Megestrol** **Tamoxifen**	Specialist use only

[10] Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on their usual brand. Any change must be under the supervision of a specialist.

[11] Enzalutamide can be supplied under the PGD if the patient is within the required monitoring period

SCHEDULE 9

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Blood and nutrition, chapter 9

Part A: All medicines in Blood and nutrition, chapter 9 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anaemias	Metabolic disorders	Mineral and trace elements deficiencies
Platelet disorders	Nutrition	Vitamin deficiency
Fluid and electrolyte imbalances		

Part B: The following medicines listed in Blood and nutrition, chapter 9 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	**Rationale**
Blood and blood-forming organs	
All injections and infusions **except**: section 1.1 section 1.3	Acute/Specialist use only
All drugs in section 2	Specialist use only
All drugs in section 3	Specialist use only
All drugs in section 4	Specialist use only
Nutrition and metabolic disorders	
All injections and infusions	Specialist use only
section 1 section 3.4 section 3.11 section 3.13 section 3.14 section 6.1a	Specialist use only
Cinacalcet granules	Hospital use only
Eliglustat	Specialist use only
Migalastat	Specialist use only
Oxymetholone	Controlled Drug
Tafamidis	Hospital use only
Voxelotor	Hospital use only

SCHEDULE 10

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Musculoskeletal system, chapter 10

Part A: All medicines in Musculoskeletal, chapter 10 of the current BNF/BNFC [12], with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Arthritis	Neuromuscular disorders
Hyperuricaemia and gout	Pain and inflammation in musculoskeletal disorders

Part B: The following medicines listed in Musculoskeletal, chapter 10 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 3.1	Hospital use only
Amifampridine	Specialist use only
Baricitinib	Specialist use only
Leflunomide [13]	Monitoring required
Tofacitinib	Specialist use only
Filgotinib	Specialist use only
Upadacitinib	Specialist use only

[12] Supply of azathioprine, ciclosporin and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page 14)

[13] Leflunomide can be supplied under the PGD if the patient is within the required monitoring period

SCHEDULE 11

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Eye, chapter 11

Part A: All medicines in Eye, chapter 11 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic and inflammatory eye conditions	Eye infections	Glaucoma and ocular hypertension
Dry eye conditions	Eye procedures	

Part B: The following medicines listed in Eye, chapter 11 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	**Rationale**
All injections and infusions	Acute/Specialist use only
All section 4 **except**: Bromfenac Diclofenac sodium Flurbiprofen Ketorolac trometamol	Acute/Specialist use only
All section 6	Specialist use only

SCHEDULE 12

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Ear, nose and oropharynx, chapter 12

Part A: All medicines in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Dry mouth	Oral hygiene	Oropharyngeal fungal infections
Nasal congestion	Otitis media	Oropharyngeal viral infections
Nasal inflammation, nasal polyps and rhinitis	Oral ulceration and inflammation	Otitis Externa
Nasal staphylococcal infection	Oropharyngeal bacterial infections	

Part B: The following medicines listed in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
Aluminium acetate	Acute use only

SCHEDULE 13

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Skin, chapter 13

Part A: All medicines in Skin, chapter 13 of the current BNF/BNFC [14], with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Dry and scaling skin disorders	Sun protection and photodamage	Skin cleansers, antiseptics and desloughing agents
Infections of the skin	Pruritus	Skin disfigurement
Inflammatory skin conditions	Rosacea and acne	Superficial soft tissue injuries and superficial thrombophlebitis
Perspiration	Scalp and hair conditions	Warts and calluses

Part B: The following medicines listed in Skin, chapter 13 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
Abrocitinib	Hospital use only
Alitretinoin	Specialist use only
Isotretinoin	Specialist use only

[14] Supply of azathioprine, ciclosporin and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page 14)

SCHEDULE 14

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Vaccines, chapter 14

Part A: All medicines in Vaccines, chapter 14 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

There are no clinical conditions.

Part B: The following medicines listed in Vaccines, chapter 14 of the current BNF/BNFC **may not** be provided under this PGD.

Excluded drug	Rationale
All chapter 14	Acute/Specialist use only

SCHEDULE 15

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Anaesthesia, chapter 15

Part A: All medicines in Anaesthesia, chapter 15 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Local anaesthesia

Part B: The following medicines listed in Anaesthesia, chapter 15 of the current BNF/BNFC **may not** be provided under this PGD.

Excluded drug	**Rationale**
All chapter 15 **except**: Lidocaine hydrochloride cream, ointment, plaster and spray Lidocaine with prilocaine cream Tetracaine gel	Acute/Specialist use only

SCHEDULE 16

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Emergency treatment of poisoning, chapter 16

Part A: All medicines in Emergency treatment of poisoning, chapter16 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Management of opioid overdose	

Part B: The following medicines listed in Emergency treatment of poisoning, chapter 16 of the current BNF/BNFC **may not** be provided under this PGD.

Excluded drug	**Rationale**
All chapter 16 **except**: Naloxone hydrochloride	Acute/Specialist use only

SCHEDULE 17

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Borderline Substances, appendix 2

Part A: All products in the Borderline Substances section, appendix 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions: [15]

Disease-related malnutrition	Intractable malabsorption	Pre-operative preparation of malnourished patients
Dysphagia	Proven inflammatory bowel disease	Following total gastrectomy
Short-bowel syndrome	Bowel fistula	Photodermatoses (skin protection in)
Dermatitis, eczema and pruritis	Disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitiligo	Dry mouth (xerostomia)

Part B: The following medicines listed in Borderline Substances, appendix 2 of the current BNF/BNFC may not be provided under this PGD.

There are no exclusions

[15] All items supplied from this section under the PGD **must be endorsed ACBS.** If required, refer to Scottish Drug Tariff section 16 for current list of allowable gluten-free products

WHAT'S NEW IN UNSCHEDULED CARE PGD version 30?

1. Medication Included and Excluded (review of BNF 84 and 85)

New medicines allowed under PGD version 30 and **can be supplied**

Similar products available for supply under the PGD, and therefore these medicines are also allowed.

- Aklief® (trifarotene)
- Aloflute® (fluticasone with salmeterol)
- Avenor® (fluticasone with salmeterol)
- Dailiport® (tacrolimus)
- Drovelis® (drospirenone with estetrol)
- Efmody® (hydrocortisone)
- Kerendia® (finerenone)
- Luforbec® (beclomethasone with formoterol)
- Magnesium citrate
- Netildex® (dexamethasone with netilmicin) acute use only
- Nettacin® (netilmicin) acute use only
- Ogluo® (glucagon)
- Orobalin® (cyanocobalamin)
- Seffalair Spiromax® (fluticasone with salmeterol)
- Sereflo Ciphaler® (fluticasone with salmeterol)
- Stalpex® (fluticasone with salmeterol)
- Trimbow 172/5/9® (beclometasone with formoterol and glycopyrronium)
- Vazkepa® (icosapent ethyl)
- Vydura® (rimegepant)
- WockAIR® (budesonide with formoterol)
- Xaqua® (metolazone)

New medicines not allowed under PGD version 30 and **cannot be supplied**

- Actimorph® (morphine) controlled drug
- Aspaveli® (pegcetacoplan) – hospital use only
- Brukinsa® (zanubrutinib) Specialist use only
- Bylvay® (odevixibat) hospital use only
- Ducressa® (dexamethasone with levofloxacin) acute use only
- Exkivity® (mobocertinib) specialist/hospital use only
- Gavreto® (pralsetinib) hospital use only
- Giapreza® (angiotensin II) hospital use only
- Givlaari® (givosiran) – hospital use only
- Hepcludex® (bulevirtide) hospital use only
- Imcivree® (setmelanotide) hospital use only
- Jemperli® (dostarlimab) – hospital use only
- Kapruvia® (difelikefalin) hospital use only

What's New? What's New v30 May 2023 Page 2 of 4

- Kimmtrak® (tebentafusp) hospital use only
- Minjuvi® (tafasitamab) – hospital use only
- NovoThirteen® (factor XIII A-subunit [recombinant]) specialist use only
- Nuvaxovid® (COVID-19 vaccine) acute use only
- Oxbryta® (voxelotor) hospital use only
- Padcev® (enfortumab vedotin) specialist use only
- Palforzia® (peanut protein) hospital use only
- Paxlovid® (nirmatrelvir with ritonavir)
- Qinlock® (ripretinib) specialist use only
- Rybrevant® (amivantamab) – hospital use only
- Scemblix® (asciminib) hospital use only
- Shingrix® (herpes-zoster vaccine, recombinant, adjuvanted) – acute use only
- Sibnayal® (potassium citrate with potassium bicarbonate) hospital use only
- Tavneos® (avacopan) hospital use only
- Tenkasi® (oritavancin) hospital use only
- Vabysmo® (faricimab) specialist use only
- Vumerity® (diroximel fumarate)
- Vyepti® (eptinezumab) hospital use only
- Welireg® (belzutifan) specialist use only
- Xerava® (eravacycline) hospital use only
- Xevudy® (sotrovimab) – hospital use only
- Xofluza® (baloxavir marboxil) – acute use only
- Nephrotrans® (sodium bicarbonate) – NHS blacklist
- Sixmo® (buprenorphine) – controlled drug
- Uxil® (dasatinib) hospital use only
- Vaxelis® (diphtheria with tetanus, pertussis, Hep B, poliomyelitis and haemophilus influenza type B vaccine) – acute use only
- Zubsolv® (buprenorphine with naloxone)

What is reasonable proof that a medicine is being prescribed to a member of the public?

The current Medicines, Ethics and Practice Guide from the Royal Pharmaceutical Society states that when providing an emergency supply to a member of the public, the conditions for supply include undertaking an interview with the person (or authorised representative) to establish there is an immediate need for the medicine, and it is not practicable for that person to obtain a prescription via the normal routes at the time they present in the pharmacy. The pharmacist must also be satisfied the medicine can be supplied, and they have confirmed the correct dose and strength the person takes.

This also applies when making a supply under this PGD. The primary source of information regarding the medicine a person has lost or run out of is that person's Emergency Care Summary (ECS). This information may also appear in a PMR if the person regularly attends your pharmacy, but if they don't have a PMR, a supply can still be made based on the information in the ECS. There may be times where, due to technical or other reasons, the ECS is unavailable. In such cases you should consider any information sources that can be provided by the person (repeat slip, empty box with pharmacy label on, verbal description only) and use your professional judgement, keeping the best interests of the person at the forefront of your decision-making at all times. You should always consider the risks associated with not supplying a medicine and the potential for that person to come to harm if you decide not to supply e.g. inhaled reliever medication for asthma.

What's New? What's New v30 May 2023 Page 3 of 4

When acting as the Responsible Pharmacist you must ensure you have access to the ECS when on duty, and this should be confirmed in advance if working as a locum. If you are unable to access ECS for technical reasons, then please contact your Health Board to have this rectified. Details of individual Health Boards can be found on the NHS Community Pharmacy website via the following link contact your Health Board. There is also guidance on accessing/troubleshooting ECS on the Community Pharmacy Scotland (cps.scot) website.

Additional footnotes added to PGD Version 30
A restructuring of the paper version of BNF 85 has meant that a number of additional footnotes have been added into some of the schedules in PGD Version 30. These should bring more clarity around what can and cannot be supplied e.g. methotrexate oral tablets and subcutaneous injection for self-administration are both allowed under this PGD.

Glucose monitoring
Since December 2022 the FreeStyle Libre Mark 1 Sensor has not been allowed for supply under this PGD. Only the FreeStyle Libre Mark 2 Sensor is now allowed and can be supplied under this PGD.

Supply of Appliances under PGD Version 30
This PGD covers the Urgent Provision of Current Prescribed Medicines, Appliances and ACBS products. Therefore, appliances such as catheters and drainage bags etc. are allowed for urgent supply provided they are listed in the most up-to-date Scottish Drug Tariff.

Supply of Medicines under Schedule 4 of PGD Version 30
There have been some changes/clarifications made to Schedule 4 of this PGD (pages 9-10), and you should review this schedule to ensure you are familiar with what can and cannot be supplied under this PGD. We've been made aware on a number of occasions that medicines suitable for supplying under this section of this PGD are not being made. We ask you to review Schedule 4 so that you are confident in which medicines are appropriate for supply, which include certain medicines used for treating pain, a range of mental health disorders (such as depression) and a number of other clinical conditions.

Supply of acutely prescribed medicines
If a prescription has been generated by the GP (or other prescriber) which has not yet reached the pharmacy when the person presents, but the item is visible within the person's ECS, you are allowed to make a supply of that medicine under this PGD. Also, if there is a need to switch the formulation of a medicine e.g. tablets to liquid, to support them in taking the medicine as prescribed, this is allowed under this PGD.

Reminders

1. Individual Authorisation Forms

When completing this form please add the pharmacy name and contractor code of your normal work location, tick the Health Board you work in, indicate your position within the pharmacy

What's New? What's New v30 May 2023 Page 4 of 4

and send to the relevant Health Board by email, post or as instructed by your health board. You can use a single form for up to three Health Boards. If doing so, tick up to three boxes and send to each Board you have selected. This will ensure you are authorised to use the PGD in the Boards indicated.

Contractors: you must ensure that at least one pharmacist has named your premises on the form, or payment cannot be made for a supply under the PGD. Pharmacists have until **31st July 2023** to sign version 30 or payment for supplies made will be stopped (unless the PGD is signed and sent for authorisation immediately before a supply is made). Individual pharmacists are reminded that they **must sign** the most recent version of the PGD, which from now on will be an annual requirement. If you do not sign and email/post each time the PGD is issued and continue to use the UCF forms for supply under this PGD, you will be acting illegally. Use your GPhC number on the Authorisation form and on UCF forms.